ArticleJournal of advanced research2026
Exploration and analysis of methylglyoxal-driven chronic inflammation in polycystic ovary syndrome.
Article in Journal of advanced research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Genistein in polycystic ovary syndrome: mechanisms, preclinical evidence, and translational potential.Frontiers in global women's health · 2026Review
- Natural Products for Polyendocrine Metabolic Ovarian Syndrome: Integrating Traditional Chinese and Western Medicine Perspectives.Drug design, development and therapy · 2026Review
- Synergistic Impact of Obesity and PCOS on Immune Dysregulation: A Review of Systemic and Local Inflammatory Profiles.International journal of women's health · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionChronic low-grade inflammation drives polycystic ovary syndrome (PCOS)-related metabolic disorders, but the underlying mechanisms remain unclear. Methylglyoxal, a key ovarian metabolite, promotes inflammation when elevated, its role in PCOS-related inflammation remains uncharacterized.
objectivesThis study aimed to identify the role of methylglyoxal in PCOS-related inflammation and its mechanisms of action.
methodsThis study recruited 258 participants from Shengjing Hospital. White blood cells, neutrophils, and lymphocytes were counted. The Olink Target 96 Inflammation Panel and untargeted metabolomics were used to determine the expression levels of inflammatory factors and metabolites. Key metabolites regulating inflammation were investigated via multiomics analysis (transcriptomics, proteomics, and metabolomics) and machine learning. The levels of methylglyoxal and inflammatory molecules were measured via ELISA. Restricted cubic spline, linear/logistic regression, and receiver operating characteristic (ROC) analyses were performed to examine the relationship between methylglyoxal levels and inflammation.
resultsMethylglyoxal levels were notably higher in the follicular fluid and serum of PCOS patients, closely linked to inflammation. Even after adjusting for confounding factors, elevated methylglyoxal levels remained an independent risk factor for inflammatory markers in PCOS patients. In PCOS, insulin resistance and dyslipidemia are associated with increased methylglyoxal concentrations and a more pronounced relationship between methylglyoxal and inflammatory processes. Compared with individuals with normal weight and low methylglyoxal levels, those who were obese or overweight and had high levels of methylglyoxal showed severe inflammatory responses. Additionally, multiomics analysis indicated that IL-17A may serve as a key downstream factor of methylglyoxal.
conclusionWe observed significantly elevated methylglyoxal levels in both the follicular fluid and serum of PCOS patients, which were strongly associated with inflammation. Serum methylglyoxal shows promise as a novel biomarker for PCOS-related metabolic-inflammatory dysregulation and may provide a novel target for the treatment of PCOS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.